• Wondering if Illumina at US$162.96 is priced for growth or still leaving some value on the table? This article walks through what the current share price might be implying.
• The stock has moved sharply in recent periods, with returns of 12.8% over 7 days, 35.4% over 30 days, 21.3% year to date and 98.2% over 1 year, while the 3 year and 5 year returns show declines of 19.1% and 59.9% respectively.
• Recent headlines around Illumina have focused on its core role in genomics and ongoing corporate developments, which some investors connect to changing expectations around the long term outlook for the business. These developments provide the backdrop many investors use when weighing whether a near doubling in the share price over 1 year is justified by fundamentals.
• Simply Wall St currently gives Illumina a valuation score of 4 out of 6, based on how often the stock screens as undervalued across several checks. The next sections compare different valuation approaches before finishing with a broader way to think about what fair value really means for this stock.

Approach 1: Illumina Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value. It is essentially asking what all those future dollars are worth in today’s terms.

For Illumina, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flow projections in $. The latest twelve month free cash flow sits at about $913.9m. Analysts and extrapolated estimates point to free cash flow of $890m in 2026 and $1,660m by 2030, with interim years stepping up between those points according to the Simply Wall St projections.

Adding up these discounted cash flows results in an estimated intrinsic value of about $245.14 per share. Compared with the current share price of $162.96, the DCF output suggests an intrinsic discount of roughly 33.5%, which indicates the stock is screening as undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Illumina is undervalued by 33.5%. Track this in your watchlist or portfolio, or discover 46 more high quality undervalued stocks.

Approach 2: Illumina Price vs Earnings

For a profitable company, the P/E ratio is a useful way to connect what you pay for the stock with the earnings it is currently generating. It tells you how many dollars investors are paying today for each dollar of annual earnings.

What counts as a “normal” P/E ratio depends a lot on expectations and risk. Higher expected earnings growth or a stronger competitive position can justify a higher P/E, while more uncertainty or weaker profitability usually lines up with a lower P/E.

Illumina currently trades on a P/E of 28.90x. That sits below the Life Sciences industry average P/E of about 34.27x, and is close to the peer group average of roughly 29.57x. Simply Wall St also calculates a “Fair Ratio” of 20.62x for Illumina, which is its view of what the P/E might be given factors such as earnings growth, industry, profit margins, market cap and company specific risks.

This Fair Ratio is more tailored than a simple comparison with peers or the wider industry because it folds those extra factors into a single benchmark. Setting Illumina’s current P/E of 28.90x against the Fair Ratio of 20.62x suggests the stock is screening as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Illumina Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story about Illumina to the numbers by spelling out what you think revenue, earnings and margins could look like, connecting that forecast to a Fair Value, then comparing it with the current price to help you decide if the stock fits your plan.

Each Narrative sits inside the Community page and is easy to use. You can pick a view that fits your own expectations. For example, one investor might focus on policy, competition and execution risks and land on a Fair Value around US$87.05. Another might lean into clinical sequencing, multiomics and operational efficiencies and anchor closer to US$156.51. A third could take the middle ground near US$136.11. All of these Narratives automatically refresh as new earnings, news and forecasts come in so your Fair Value view is kept current without extra work from you.

Do you think there's more to the story for Illumina? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.